Bengaluru: Samsung Medison has completed the acquisition of Sonio SAS. The closing of the transaction was subject to applicable regulatory approvals, notably the approval of the French Ministry of the Economy and Finance. Following the completion of the transaction, Sonio will remain an independent company headquartered in France and will continue its commercial growth independently.
Sonio was established in 2020 with a mission to enhance women and children’s health globally. The company developed industry leading IT solutions and AI assistant features for obstetrics and gynaecology ultrasound that robustly assisted medical professionals in the evaluation and documentation of ultrasound exams.
Sonio Detect, an FDA 510(k) cleared AI assistant, provides accurate feedback on ultrasound examination quality and demonstrates remarkable performance with over 90 per cent sensitivity in recognising foetal ultrasound views. Together with Sonio’s AI expertise, Samsung Medison’s ultrasound systems will help bring to market, breakthrough AI-enhanced workflows and accelerate innovation in patient outcomes and quality of prenatal care.
Deepak Prakash, CTO, Sonio SAS, said, “Together, Samsung and Sonio aim to bring about a transformational shift in prenatal ultrasound examinations that would especially be a gamechanger in developing regions of the world including India,”
Yong Kwan Kim, CEO Samsung Medison, said, “The collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities.”
Cécile Brosset, CEO and Co-founder, Sonio, said, “In addition to close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare.”
